Tradipitant

Tradipitant
Legal status
Legal status
  • Investigational
Identifiers
  • (2-(1-(3,5-Bis(trifluoromethyl)benzyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)(2-chlorophenyl)methanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H16ClF6N5O
Molar mass587.91 g·mol−1
3D model (JSmol)
  • Clc1ccccc1C(=O)c2c(nccc2)c3nnn(c3c4ccncc4)Cc5cc(cc(c5)C(F)(F)F)C(F)(F)F
  • InChI=1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2
  • Key:CAVRKWRKTNINFF-UHFFFAOYSA-N

Tradipitant (VLY-686 or LY686017) is an experimental drug that is a neurokinin 1 antagonist. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Eli Lilly and named LY686017. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012.[1] Vanda Pharmaceuticals is a U.S. pharmaceutical company that as of November 2015 only has three drugs in their product pipeline: tasimelteon, VLY-686, and iloperidone.[2]

  1. ^ "Company Overview of Eli Lilly & Co., Worldwide License to Develop and Commercialize VLY-686". Bloomberg Business. Retrieved 16 November 2015.
  2. ^ "Product Pipeline". Vanda Pharmaceuticals Inc. Archived from the original on 27 March 2016.